In drug discovery, what step occurs immediately after target identification?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

In drug discovery, what step occurs immediately after target identification?

After identifying a potential target, the next step is to validate it. Target validation proves that modulating this target actually affects the disease biology in a meaningful and druggable way. It answers whether altering the target’s activity can produce a therapeutic benefit and whether doing so is feasible with a modulator that has an acceptable safety profile. This is tested with complementary approaches: genetic methods such as knockdown or knockout to show that reducing or increasing target activity changes disease-related outcomes, and pharmacological methods using tool compounds to demonstrate that chemical modulation of the target produces the desired effect. Researchers assess effects in relevant cellular models and animal systems, and they gather pharmacodynamic readouts to confirm that target engagement translates to a biological response. If the target passes these checks, there’s justification to invest in finding actual drug candidates and conducting lead discovery and optimization. Without validation, jumping straight into lead discovery risks chasing targets that aren’t truly disease-driving, aren’t druggable, or may cause unacceptable safety issues. Preclinical testing and clinical trials come later, after validated biology has been translated into viable drug candidates.

After identifying a potential target, the next step is to validate it. Target validation proves that modulating this target actually affects the disease biology in a meaningful and druggable way. It answers whether altering the target’s activity can produce a therapeutic benefit and whether doing so is feasible with a modulator that has an acceptable safety profile.

This is tested with complementary approaches: genetic methods such as knockdown or knockout to show that reducing or increasing target activity changes disease-related outcomes, and pharmacological methods using tool compounds to demonstrate that chemical modulation of the target produces the desired effect. Researchers assess effects in relevant cellular models and animal systems, and they gather pharmacodynamic readouts to confirm that target engagement translates to a biological response. If the target passes these checks, there’s justification to invest in finding actual drug candidates and conducting lead discovery and optimization.

Without validation, jumping straight into lead discovery risks chasing targets that aren’t truly disease-driving, aren’t druggable, or may cause unacceptable safety issues. Preclinical testing and clinical trials come later, after validated biology has been translated into viable drug candidates.

More practice questions